Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + placebo
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Fulvestrant is a selective estrogen receptor degrader (SERD) used in the treatment of hormone receptor-positive (HR+) metastatic breast cancer. This specific regimen, "fulvestrant + placebo," represents the control arm of the Phase II ZAMBONEY trial (NCT00900120) conducted by the Ontario Clinical Oncology Group (OCOG). In this study, postmenopausal women with bone-only or bone-predominant HR+ metastatic breast cancer received 500 mg of fulvestrant via intramuscular injection on a specific schedule (Days 1, 15, 29, and then monthly) combined with a daily oral placebo. Fulvestrant's mechanism involves binding to the estrogen receptor, blocking its action, and inducing its degradation, which effectively downregulates the estrogen signaling pathway necessary for the proliferation of HR+ tumor cells.
- Brand names
- Faslodex
- Other names
- fulvestrant + placebo-Ontario Clinical Oncology Group (OCOG)-breast cancer (metastatic)ZAMBONEY trial control arm
02
Targets
ESR2 (ERβ)ESR1 (ERα)
Beyond the preview
Go deeper on fulvestrant + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + placebo.